These summaries of our completed research projects highlight what work was undertaken, which aims were achieved and where the research is going next.
It's estimated that about half of people admitted to hospital with a stroke will have lost control of their bladder, and a third will experience loss of bowel control. Last week, a research incontinence workshop was held at Guy's Hospital London, with the aim of stimulating research into incontinence.
CADASIL is one of the most common genetic causes of stroke and dementia. Currently there is no treatment for CADASIL. In this study, human stem cells will be generated from a piece of skin donated by patients with CADASIL. From these stem cells, smooth muscle cells (SMCs) will be generated in a tissue culture dish in the lab.
The National Institute of Clinical Excellence (NICE) are currently welcoming applications from people who would like to join the groups that develop Quality Standards.
A panel of independent experts has decided that alteplase, a clot-busting drug often used to treat strokes is safe and effective under current guidelines.
Published in the journal Age and Ageing, a new systematic review of the current research suggests that anticoagulant drugs may have cognitive benefit for those with AF (atrial fibrillation).
No two strokes are alike - the damage from each stroke leaves its own unique signature on a person's brain and behaviour. The current project will investigate how different types of stroke affect a person's long term recovery or deterioration
Raconteur is a publishing house and agency which produces special reports and commentary for the Times and Sunday Times.
Published on Saturday 9 May 2015, the 'Understanding Stroke 2015' report consists of a number articles covering different areas of current stroke news.
The European Stroke Organisation Conference (ESOC) 2018 is currently on from 16-18 May in Gothenburg, Sweden. The first day of ESOC included some truly inspiring scientific sessions, including the WAKE-UP trial, RIGHT-2 trial and CROMIS-2 trials.